Brief: Sosei Heptares And Abbvie Enter New Multi-Target Collaboration To Discover, Develop And Commercialize Novel Medicines Targeting Neurological Diseases
02/08/2022 24:16
Aug 1 (Reuters) - Sosei Group Corp 4565.T :
* SOSEI HEPTARES AND ABBVIE ENTER NEW MULTI-TARGET
COLLABORATION
TO DISCOVER, DEVELOP AND COMMERCIALIZE NOVEL MEDICINES TARGETING
NEUROLOGICAL DISEASES
* SOSEI- CO ELIGIBLE TO RECEIVE UP TO $80 MILLION UPFRONT,
NEAR-TERM MILESTONE PAYMENTS
* SOSEI- CO HAS POTENTIAL TO RECEIVE FURTHER DOWNSTREAM
PAYMENTS
TOTALLING UP TO US$1.2 BILLION, PLUS TIERED ROYALTIES
Source text for Eikon: urn:newsml:reuters.com:*:nGNX9Wb103
Further company coverage: 4565.T
((Reuters.briefs@thomsonreuters.com;))
Recent news on Nxera Pharma
See all newsNxera Pharma Submits Marketing Authorization Application For Vamorolone In South Korea For Treatment Of Duchenne Muscular Dystrophy
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Nxera Pharma - Entered Into Exclusive License, Supply And Commercialization Agreement With Synmosa For Quviviq Across Eight Asia-Pacific Markets
Brief: Nxera Announces Successful Resolution Of Minig Patent Infringement Action
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up